Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: a case series report
Jiaying Zhang,
Yuan Gao,
Xiaoyun Miao
и другие.
Frontiers in Immunology,
Год журнала:
2025,
Номер
15
Опубликована: Янв. 17, 2025
The
treatment
of
COVID-19
in
the
post-transplant
individuals
is
challenging,
primarily
due
to
drug-drug
interaction
between
nirmatrelvir/ritonavir
and
tacrolimus.
Deuremidevir
hydrobromide
tablets
(VV116)
an
orally
small
molecule
agents
target
SARS-CoV-2
RdRp
inhibits
viral
replication.
It
may
have
a
low
likelihood
interactions
has
potential
provide
new
option.
We
described
three
cases
renal
transplant
patients
with
concomitant
impaired
function
who
developed
pneumonia
were
treated
VV116.
Despite
varying
degrees
drug
accumulation,
these
achieved
rapid
clearance
showed
prompt
improvement
symptoms.
Notably,
tacrolimus
blood
concentrations
remained
within
therapeutic
range
throughout
treatment,
no
clinically
significant
adverse
events
observed
despite
accumulation.
Язык: Английский
Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report
Frontiers in Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Фев. 25, 2025
VV116
is
an
oral
antiviral
drug
against
SARS-CoV-2,
known
for
its
favorable
efficacy
and
safety
profile.
But
application
in
patients
with
severe
liver
dysfunction
has
not
been
evaluated.
Here,
we
report
a
case
which
patient
aplastic
anemia
impairment
(recovery
phase
of
acute
failure)
was
infected
SARS-CoV-2.
Based
on
clinical
trials
pharmacokinetic
analysis
about
VV116,
initiated
reduced
dose
300
mg
every
12
h
day
1,
200
days
2-5
therapy.
Finally,
the
patient's
viral
load
rapidly
dropped
to
undetected
level,
no
drug-related
adverse
effects
were
observed.
Язык: Английский